BRAF inhibitor

Cat. No.: HY-10247

CAS No.: 918505-61-0

Molecular Formula: $C_{22}H_{18}F_2N_4O_3S$

Molecular Weight: 456.47

Target: Raf

Pathway: MAPK/ERK Pathway

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (109.54 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.1907 mL	10.9536 mL	21.9072 mL
5 mM	0.4381 mL	2.1907 mL	4.3814 mL
10 mM	0.2191 mL	1.0954 mL	2.1907 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.48 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.48 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.48 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BRAF inhibitor is a B-Raf inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.

IC_{50} & Target

B-Raf

CUSTOMER VALIDATION

- Cell Death Dis. 2022 Jul 15;13(7):615.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Prahbha N. Ibrahim, et al. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors. WO2007002325A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA